The synthesis of new adenosine A3 selective ligands containing bioisosteric isoxazoles.
The synthesis and purinergic receptor binding of novel adenosine A3 ligands is described. Many selective A3 receptor agonists e.g. N-(3-iodobenzyl)adenosine-5'-methyluronamide (IB-MECA) contain a 4'-ribosylalkylamide moiety. We found that this amide and other 4'-functional groups could be replaced with an isosteric isoxazole, and the target molecules retained potent binding to the recombinant human A3 receptor.
Mogensen
J P
JP
Novo Nordisk A/S, Måløv, Denmark.
Roberts
S M
SM
Bowler
A N
AN
Thomsen
C
C
Knutsen
L J
LJ
D000241:Adenosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D006801:Humans; D007555:Isoxazoles / Q000737:chemistry*; D008024:Ligands; D051381:Rats; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D013329:Structure-Activity Relationship
D007555:Isoxazoles; D008024:Ligands; D018047:Receptors, Purinergic P1; D011994:Recombinant Proteins; C084956:N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; D000241:Adenosine